Joel Greenblatt's position in Adma Biologics is currently worth $3.33 Million. That's 0.03% of their equity portfolio (565th largest holding). The first Adma Biologics trade was made in Q4 2022. Since then Joel Greenblatt bought shares five more times and sold shares on three occasions. The stake costed the investor $1.51 Million, netting the investor a gain of 121% so far.